Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

DSM staff profile

Dr Rebecca Roberts

PositionSenior Research Fellow
DepartmentDepartment of Surgical Sciences (DSM)
QualificationsBSc(Hons) PhD
Research summaryGenetics and autoimmune diseases

Research

Rebecca's primary area of research is the identification and characterisation of genes that alter susceptibility to chronic inflammatory diseases (e.g. Crohn's disease, ulcerative colitis, ankylosing spondylitis), and genes that influence response to drugs used to manage these debilitating conditions.

Rebecca is currently funded by a Health Research Council (HRC) project grant investigating novel genetic risk factors for inflammatory bowel disease. This project is part of a larger HRC programme looking at the pathogenesis of common chronic conditions.

Publications

Roberts, R. L., Wallace, M. C., Phipps-Green, A. J., Topless, R., Drake, J. M., Tan, P., … Merriman, T. R., & Stamp, L. K. (2017). ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics Journal, 17, 201-203. doi: 10.1038/tpj.2015.101

Lee, J. C., Biasci, D., Roberts, R., Gearry, R. B., Mansfield, J. C., Ahmed, T., … Smith, K. G. C. (2017). Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nature Genetics, 49, 262-268. doi: 10.1038/ng.3755

Saffian, S. M., Duffull, S. B., Roberts, R. L., Tait, R. C., Black, L., Lund, K. A., … Wright, D. F. B. (2016). Influence of genotype on warfarin maintenance dose predictions produced using a Bayesian dose individualization tool. Therapeutic Drug Monitoring, 38(6), 677-683. doi: 10.1097/ftd.0000000000000347

Roberts, R. L., & Stamp, L. K. (2015). Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics, 16(6), 619-629. doi: 10.2217/pgs.15.16

Saffian, S. M., Wright, D. F. B., Roberts, R. L., & Duffull, S. B. (2015). Methods for predicting warfarin dose requirements. Therapeutic Drug Monitoring, 37(4), 531-538. doi: 10.1097/ftd.0000000000000177

Journal - Research Article

Roberts, R. L., Wallace, M. C., Phipps-Green, A. J., Topless, R., Drake, J. M., Tan, P., … Merriman, T. R., & Stamp, L. K. (2017). ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics Journal, 17, 201-203. doi: 10.1038/tpj.2015.101

Saffian, S. M., Duffull, S. B., Roberts, R. L., Tait, R. C., Black, L., Lund, K. A., … Wright, D. F. B. (2016). Influence of genotype on warfarin maintenance dose predictions produced using a Bayesian dose individualization tool. Therapeutic Drug Monitoring, 38(6), 677-683. doi: 10.1097/ftd.0000000000000347

Roberts, R. L., & Stamp, L. K. (2015). Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics, 16(6), 619-629. doi: 10.2217/pgs.15.16

Saffian, S. M., Wright, D. F. B., Roberts, R. L., & Duffull, S. B. (2015). Methods for predicting warfarin dose requirements. Therapeutic Drug Monitoring, 37(4), 531-538. doi: 10.1097/ftd.0000000000000177

Doecke, J. D., Simms, L. A., Zhao, Z. Z., Roberts, R. L., Fowler, E. V., Croft, A., … Barclay, M. L., Merriman, T. R., Gearry, R. B., … Radford-Smith, G. L. (2015). Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease. Journal of Gastroenterology & Hepatology, 30(2), 299-307. doi: 10.1111/jgh.12674

Roberts, R. L., Wallace, M. C., Harrison, A., Dalbeth, N., Merriman, T. R., & Stamp, L. K. (2015). A human leukocyte antigen locus haplotype confers risk for allopurinol-related adverse effects in Caucasian patients with gout. Pharmacogenetics & Genomics, 25(8), 412-415. doi: 10.1097/fpc.0000000000000147

Roberts, R. L., & Barclay, M. L. (2015). Update on thiopurine pharmacogenetics in inflammatory bowel disease. Pharmacogenomics, 16(8), 891-903. doi: 10.2217/pgs.15.29

Roberts, R. L., Wallace, M. C., Wright, D. F. B., Cadzow, M., Dalbeth, N., Jones, P. B., Stamp, L. K., Harrison, A. A., Black, M. A., & Merriman, T. R. (2014). Frequency of CYP2C9 polymorphisms in Polynesian people and potential relevance to management of gout with benzbromarone. Joint Bone Spine, 81(2), 160-163. doi: 10.1016/j.jbspin.2013.07.006

Chin, P. K. L., Wright, D. F. B., Zhang, M., Wallace, M. C., Roberts, R. L., Patterson, D. M., Jensen, B. P., Barclay, M. L., & Begg, E. J. (2014). Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. Drugs in R&D, 14(2), 113-123. doi: 10.1007/s40268-014-0045-9

Stamp, L. K., Merriman, T. R., Barclay, M. L., Singh, J. A., Roberts, R. L., Wright, D. F. B., & Dalbeth, N. (2014). Impaired response or insufficient dosage? Examining the potential causes of ”inadequate response” to allopurinol in the treatment of gout. Seminars in Arthritis & Rheumatism, 44(2), 170-174. doi: 10.1016/j.semarthrit.2014.05.007

Nasir, B. F., Griffiths, L. R., Nasir, A., Roberts, R., Barclay, M., Gearry, R. B., & Lea, R. A. (2013). An envirogenomic signature is associated with risk of IBD-related surgery in a population-based Crohn’s disease cohort. Journal of Gastrointestinal Surgery, 17(9), 1643-1650. doi: 10.1007/s11605-013-2250-1

Roberts, R. L., Wallace, M. C., Jones, G. T., van Rij, A. M., Merriman, T. R., Harrison, A., … Stamp, L. K., … Highton, J., & Stebbings, S. M. (2013). Prevalence of HLA-B27 in the New Zealand population: Effect of age and ethnicity. Arthritis Research & Therapy, 15, R158. doi: 10.1186/ar4341

Falvey, J. D., Bentley, R. W., Merriman, T. R., Hampton, M. B., Barclay, M. L., Gearry, R. B., & Roberts, R. L. (2013). Macrophage migration inhibitory factor gene polymorphisms in inflammatory bowel disease: An association study in New Zealand Caucasians and meta-analysis. World Journal of Gastroenterology, 19(39), 6656-6664. doi: 10.3748/wjg.v19.i39.6656

Nasir, B. F., Griffiths, L., Nasir, A., Roberts, R., Barclay, M., Gearry, R., & Lea, R. A. (2013). Perianal disease combined with NOD2 genotype predicts need for IBD-related surgery in Crohn's disease patients from a population-based cohort. Journal of Clinical Gastroenterology, 47(3), 242-245. doi: 10.1097/MCG.0b013e318258314d

Doecke, J. D., Simms, L. A., Zhao, Z. Z., Huang, N., Hanigan, K., Krishnaprasad, K., Roberts, R. L., … Gearry, R. B., … Radford-Smith, G. L. (2013). Genetic susceptibility in IBD: Overlap between ulcerative colitis and Crohn's disease. Inflammatory Bowel Diseases, 19(2), 240-245. doi: 10.1097/MIB.0b013e3182810041

Ngu, J. H., Wallace, M. C., Merriman, T. R., Gearry, R. B., Stedman, C. A. M., & Roberts, R. L. (2013). Association of the HLA locus and TNF with type I autoimmune hepatitis susceptibility in New Zealand Caucasians. SpringerPlus, 2(1), 355. doi: 10.1186/2193-1801-2-355

Lee, J. C., Espéli, M., Anderson, C. A., Linterman, M. A., Pocock, J. M., Williams, N. J., Roberts, R., … Gearry, R., … Smith, K. G. C. (2013). Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell, 155(1), 57-69. doi: 10.1016/j.cell.2013.08.034

International Multiple Sclerosis Genetic Consortium (IMSGC), and also Mason, D., Barclay, M., Roberts, R., & Gearry, R. (2013). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 45(11), 1353-1360. doi: 10.1038/ng.2770

Beaudoin, M., Goyette, P., Boucher, G., Lo, K. S., Rivas, M. A., Stevens, C., … and also Barclay, M., Gearry, R., & Roberts, R. (2013). Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genetics, 9(9), e1003723. doi: 10.1371/journal.pgen.1003723

Roberts, R. L., & Barclay, M. L. (2012). Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. Journal of Gastroenterology & Hepatology, 27(10), 1546-1554. doi: 10.1111/j.1440-1746.2012.07220.x

Bentley, R. W., Keown, D. A., Gearry, R. B., Cameron, V. A., Keenan, J., Roberts, R. L., & Day, A. S. (2012). Vitamin D receptor polymorphisms in colorectal cancer in New Zealand: An association study. New Zealand Medical Journal, 125(1356). Retrieved from http://www.nzma.org.nz/journal

Stamp, L. K., Hazlett, J., Roberts, R. L., Frampton, C., Highton, J., & Hessian, P. A. (2012). Adenosine receptor expression in rheumatoid synovium: A basis for methotrexate action. Arthritis Research & Therapy, 14, R138. doi: 10.1186/ar3871

Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P. B., Hui, K. Y., … Gearry, R., … and also Barclay, M., & Roberts, R. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119-124. doi: 10.1038/nature11582

Roberts, R. L., Gallo, L.-M. D., Barclay, M. L., Gómez-García, M., Cardeña, C., Merriman, T. R., Gearry, R. B., & Martin, J. (2012). Independent replication of an association of CNVR7113.6 with Crohn's disease in caucasians. Inflammatory Bowel Diseases, 18(2), 305-311. doi: 10.1002/ibd.21752

Jensen, B. P., Roberts, R. L., Vyas, R., Bonke, G., Jardine, D. L., & Begg, E. J. (2012). Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers. British Journal of Clinical Pharmacology, 73(4), 619-628. doi: 10.1111/j.1365-2125.2011.04126.x

Vella-Brincat, J. W. A., Begg, E. J., Jensen, B. P., Chin, P. K. L., Roberts, R. L., Fairhall, M., … Reid, K. (2012). The pharmacokinetics and pharmacogenetics of the antiemetic cyclizine in palliative care patients. Journal of Pain & Symptom Management, 43(3), 540-548. doi: 10.1016/j.jpainsymman.2011.04.022

Jensen, B. P., Chin, P. K. L., Roberts, R. L., & Begg, E. J. (2012). Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. British Journal of Clinical Pharmacology, 74(5), 797-805. doi: 10.1111/j.1365-2125.2012.04259.x

Eglinton, T. W., Roberts, R., Pearson, J., Barclay, M., Merriman, T. R., Frizelle, F. A., & Gearry, R. B. (2012). Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. American Journal of Gastroenterology, 107, 589-596. doi: 10.1038/ajg.2011.437

Rossin, E. J., Lage, K., Raychaudhuri, S., Xavier, R. J., Tatar, D., Benita, Y., International Inflammatory Bowel Disease Genetics Constortium, … and also Roberts, R., Barclay, M., & Gearry, R. (2011). Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genetics, 7(1), e1001273. doi: 10.1371/journal.pgen.1001273

Anderson, C. A., Boucher, G., Lees, C. W., Franke, A., D’Amato, M., Taylor, K. D., … Barclay, M., … Roberts, R., … Gearry, R., … Rioux, J. D. (2011). Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genetics, 43(3), 246-254. doi: 10.1038/ng.764

Stamp, L. K., & Roberts, R. L. (2011). Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics, 12(10), 1449-1463. doi: 10.2217/pgs.11.86

Diaz-Gallo, L.-M., Espino-Paisán, L., Fransen, K., Gómez-García, M., van Sommeren, S., Cardeña, C., … Barclay, M. L., … Gearry, R. B., Roberts, R. L., … Merriman, T. R., … Martin, J. (2011). Differential association of two PTPN22 coding variants with Crohn's disease and ulcerative colitis. Inflammatory Bowel Diseases, 17(11), 2287-2294. doi: 10.1002/ibd.21630

Roberts, R. L., Hollis-Moffatt, J. E., Gómez-García, M., Fransen, K., Ponsioen, C. Y., Crusius, B. A., … Merriman, T. R., Barclay, M. L., Gearry, R. B., & Alizadeh, B. Z. (2011). Association of the protein-tyrosine phosphatase nonreceptor type substrate 1 (PTPNS1) gene with inflammatory bowel disease. Inflammatory Bowel Diseases, 17(2), E19-E21. doi: 10.1002/ibd.21470

Glubb, D. M., Gearry, R. B., Barclay, M. L., Roberts, R. L., Pearson, J., Keenan, J. I., McKenzie, J., & Bentley, R. W. (2011). NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease. World Journal of Gastroenterology, 17(23), 2829-2837. doi: 10.3748/wjg.v17.i23.2829

Rivas, M. A., Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y., Zhang, C. K., … and also Barclay, M., Roberts, R., & Gearry, R. (2011). Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nature Genetics, 43(11), 1066-1073. doi: 10.1038/ng.952

Roberts, R. L., van Rij, A. M., Phillips, L. V., Young, S., McCormick, S. P. A., Merriman, T. R., & Jones, G. T. (2011). Interaction of the inflammasome genes CARD8 and NLRP3 in abdominal aortic aneurysms. Atherosclerosis, 218(1), 123-126. doi: 10.1016/j.atherosclerosis.2011.04.043

Stebbings, S., Jenks, K., Roberts, R., & Schultz, M. (2010). The immune response to gut bacteria in spondyloarthritis: A role in pathogenesis? Journal of Clinical Rheumatology & Musculoskeletal Medicine, 1(2).

Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., … Roberts, R., … Barclay, M., … Gearry, R., … Parkes, M. (2010). Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics, 42(12), 1118-1125. doi: 10.1038/ng.717

Weersma, R. K., Crusius, J. B. A., Roberts, R. L., Koeleman, B. P. C., Palomino-Morales, R., Wolfkamp, S., Hollis-Moffatt, J. E., … Gearry, R. B., Barclay, M. L., … Merriman, T. R., … Alizadeh, B. Z. (2010). Association of FcgR2a, but not FcgR3a, with inflammatory bowel diseases across three Caucasian populations. Inflammatory Bowel Diseases, 16(12), 2080-2089. doi: 10.1002/ibd.21342

Bentley, R. W., Cleynen, I., Gearry, R. B., Barclay, M. L., Rutgeerts, P., Merriman, T. R., … Roberts, R. L., & Vermeire, S. (2010). Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. Genes & Immunity, 11, 509-514. doi: 10.1038/gene.2010.15

Stamp, L. K., Chapman, P. T., O'Donnell, J. L., Zhang, M., James, J., Frampton, C., Barclay, M. L., Kennedy, M. A., & Roberts, R. L. (2010). Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. Pharmacogenetics & Genomics, 20(6), 367-376. doi: 10.1097/FPC.0b013e3283398a71

Simms, L. A., Doecke, J. D., Roberts, R. L., Fowler, E. V., Zhao, Z. Z., McGuckin, M. A., … McCallum, R., … Barclay, M. L., Gearry, R. B., Merriman, T. R., … Radford-Smith, G. L. (2010). KCNN4 gene variant is associated with ileal Crohn's disease in the Australian and New Zealand population. American Journal of Gastroenterology, 105, 2209-2217. doi: 10.1038/ajg.2010.161

Stewart, L. C., Day, A. S., Pearson, J., Barclay, M. L., Gearry, R. B., Roberts, R. L., & Bentley, R. W. (2010). SLC11A1 polymorphisms in inflammatory bowel disease and Mycobacterium avium subspecies paratuberculosis status. World Journal of Gastroenterology, 16(45), 5727-5731. doi: 10.3748/wjg.v16.i45.5727

Harley, J., Roberts, R., Joyce, P., Mulder, R., Luty, S., Frampton, C., & Kennedy, M. (2010). Orosomucoid influences the response to antidepressants in major depressive disorder. Journal of Psychopharmacology, 24(4), 531-535. doi: 10.1177/0269881109105101

Bentley, R. W., Pearson, J., Gearry, R. B., Barclay, M. L., McKinney, C., Merriman, T. R., & Roberts, R. L. (2010). Association of higher DEFB4 genomic copy number with Crohn's disease. American Journal of Gastroenterology, 105(2), 354-359. doi: 10.1038/ajg.2009.582

Roberts, R. L., Topless, R. K. G., Phipps-Green, A. J., Gearry, R. B., Barclay, M. L., & Merriman, T. R. (2010). Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes & Immunity, 11, 351-356. doi: 10.1038/gene.2010.11

Sharp, C. F., Gardiner, S. J., Jensen, B. P., Roberts, R. L., Troughton, R. W., Lainchbury, J. G., & Begg, E. J. (2009). CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenomics Journal, 9(3), 175-184. doi: 10.1038/tpj.2009.9

Petermann, I., Huebner, C., Browning, B. L., Gearry, R. B., Barclay, M. L., Kennedy, M., Roberts, R., … Han, D. Y., & Ferguson, L. R. (2009). Interactions among genes influencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Human Immunology, 70, 440-446. doi: 10.1016/j.humimm.2009.03.002

Bentley, R. W., Keenan, J. I., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Roberts, R. L. (2008). Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. American Journal of Gastroenterology, 103(5), 1168-1172. doi: 10.1111/j.1572-0241.2007.01742.x

Lea, R. A., Roberts, R. L., Green, M. R., Kennedy, M. A., & Chambers, G. K. (2008). Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Māori. New Zealand Medical Journal, 121(1272). Retrieved from http://journal.nzma.org.nz/journal/121-1272/3002/content.pdf

Roberts, R. L., Gearry, R. B., Bland, M. V., Sies, C. W., George, P. M., Burt, M., … Barclay, M. L., & Kennedy, M. A. (2008). Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity. Pharmacogenetics & Genomics, 18(5), 434-438.

Roberts, R. L., Gearry, R. B., Kennedy, M. A., & Barclay, M. L. (2008). Beyond TPMT: Genetic influences on thiopurine drug responses in inflammatory bowel disease. Personalized Medicine, 5(3), 233-248. doi: 10.2217/17410541.5.3.233

Roberts, R. L., Hollis-Moffatt, J. E., Gearry, R. B., Kennedy, M. A., Barclay, M. L., & Merriman, T. R. (2008). Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort. Genes & Immunity, 9(6), 561-565. doi: 10.1038/gene.2008.49

Gearry, R. B., Roberts, R. L., Burt, M. J., Frampton, C. M. A., Chapman, B. A., Collett, J. A., Shirley, P., Allington, M. D. E., Kennedy, M. A., & Barclay, M. L. (2007). Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflammatory Bowel Diseases, 13(10), 1220-1227.

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2007). IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics Journal, 7(5), 312-317.

Roberts, R. L., Gearry, R. B., Hollis-Moffatt, J. E., Miller, A. L., Reid, J., Abkevich, V., … Merriman, T. R., Barclay, M. L., & Kennedy, M. A. (2007). IL23R R381Q and ATG16L1 T300A are strongly associated with Crohn's disease in a study of New Zealand Caucasians with inflammatory bowel disease. American Journal of Gastroenterology, 102, 2754-2761.

Roberts, R. L., & Kennedy, M. A. (2006). Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clinica Chimica Acta, 366, 348-351.

Roberts, R. L., Gearry, R. B., Allington, M. D. E., Morrin, H. R., Robinson, B. A., & Frizelle, F. A. (2006). Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. Cancer Research, 66(5), 2532-2535.

Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., Barclay, M. L., & Begg, E. J. (2006). Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. British Journal of Clinical Pharmacology, 62(4), 453-456.

Gearry, R. B., Barclay, M. L., Roberts, R. L., Harraway, J., Zhang, M., Pike, L. S., George, P. M., & Florkowski, C. M. (2005). Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: Early experience of use in clinical practice. Internal Medicine Journal, 35, 580-585.

Roberts, R. L., Luty, S. E., Mulder, R. T., Joyce, P. R., & Kennedy, M. A. (2004). Association between cytochrome P450 2D6 genotype and harm avoidance. American Journal of Medical Genetics Part B, 127B, 90-93. Wiley-Liss Inc.

Roberts, R. L., Mulder, R. T., Joyce, P. R., Luty, S. E., & Kennedy, M. A. (2004). No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Human Psychopharmacology, 19(1), 17-23.

Roberts, R. L., Barclay, M. L., Gearry, R. B., & Kennedy, M. A. (2004). A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clinica Chimica Acta, 341(1-2), 49-53.

Gearry, R. B., Roberts, R. L., Barclay, M. L., & Kennedy, M. A. (2004). Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics, 14(11), 779-781.

Clark, D. W. J., Donnelly, E., Coulter, D. M., Roberts, R. L., & Kennedy, M. A. (2004). Linking pharmacovigilance with pharmacogenetics. Drug Safety, 27(15), 1171-1184.

Roberts, R. L., Gearry, R. B., Barclay, M. L., & Kennedy, M. A. (2004). Rapid detection of common CARD15 variants in patients with inflammatory bowel disease. Molecular Diagnosis, 8(2), 101-105.

Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., Chapman, B. A., Roberts, R., & Kennedy, M. A. (2003). Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 18, 395-400.

Barclay, M. L., Sawyers, S. M., Begg, E. J., Zhang, M., Roberts, R., Kennedy, M. A., & Elliott, J. M. (2003). Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics, 13(10), 627-632.

Stedman, C. A. M., Begg, E. J., Kennedy, M. A., Roberts, R., & Wilkinson, T. J. (2002). Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Human Psychopharmacology, 17(4), 187-190.

Roberts, R., Begg, E. J., Joyce, P. R., & Kennedy, M. A. (2002). How the pharmacogenetics of cytochrome P450 enzymes may affect prescribing. New Zealand Medical Journal, 115(1150), 137-140.

Roberts, R. L., Joyce, P. R., Mulder, R. T., Begg, E. J., & Kennedy, M. A. (2002). A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics Journal, 2(3), 191-196. doi: 10.1038/sj.tpj.6500099

Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R., & Barclay, M. L. (2001). Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? British Journal of Clinical Pharmacology, 51, 627-630.

Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R. L., & Barclay, M. L. (2000). Cytochrome P450 2C9 genotype does not predict incidence of gastric bleeding with non steroidal anti-inflammatory drugs. Proceedings of ASCEPT, 7(April), 57.

Roberts, R., Sullivan, P., Joyce, P. R., & Kennedy, M. A. (2000). Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction. Human Mutation, 16, 77-85.

^ Top of page

Journal - Research Other

Lee, J. C., Biasci, D., Roberts, R., Gearry, R. B., Mansfield, J. C., Ahmed, T., … Smith, K. G. C. (2017). Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nature Genetics, 49, 262-268. doi: 10.1038/ng.3755

Roberts, R. L., Wallace, M. C., Drake, J. M., & Stamp, L. K. (2014). Identification of a novel thiopurine S-methyltransferase allele (TPMT*37) [Short communication]. Pharmacogenetics & Genomics, 24(6), 320-323. doi: 10.1097/fpc.0000000000000049

Roberts, R. L., Wallace, M. C., Seinen, M. L., Krishnaprasad, K., Chew, A., Lawrance, I., … Barclay, M. L. (2014). PACSIN2 does not influence thiopurine-related toxicity in patients with inflammatory bowel disease. American Journal of Gastroenterology, 109, 925-927. doi: 10.1038/ajg.2014.89

Hollis-Moffatt, J. E., Gearry, R. B., Barclay, M. L., Merriman, T. R., & Roberts, R. L. (2010). Consolidation of evidence for association of the KIAA1109-TENR-IL2-IL21 rs6822844 variant with Crohn's disease [Letter]. American Journal of Gastroenterology, 105(5), 1204-1205. doi: 10.1038/ajg.2010.34

Roberts, R. L., Zhang, M., Marinaki, A. M., & Stamp, L. K. (2010). Does genetic variability in aldehyde oxidase and molybdenum cofactor sulfurase predict nonresponse to allopurinol? [Letter to the editors]. Alimentary Pharmacology & Therapeutics, 32(2), 310-311. doi: 10.1111/j.1365-2036.2010.04349.x

Roberts, R. L., Gearry, R. B., & Barclay, M. L. (2010). Allopurinol—thiopurine combination therapy in inflammatory bowel disease: Are there genetic clues to this puzzle? [Editorial]. Pharmacogenomics, 11(11), 1505-1508. doi: 10.2217/pgs.10.143

Schultz, M., Roberts, R. L., & Butt, A. G. (2010). Understanding probiotic treatment strategies in inflammatory bowel disease, with a special emphasis on the intestinal barrier. European Gastroenterology & Hepatology Review, 6(1), 58-65.

Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Barclay, M. L., Kennedy, M. A., Frampton, C. M. A., & Roberts, R. L. (2009). Lack of association between HLA-G 14 bp insertion/deletion polymorphism and response to longterm therapy with methotrexate response in rheumatoid arthritis [Letter]. Annals of the Rheumatic Diseases, 68(1), 154-155. doi: 10.1136/ard.2008.089383

Gardiner, S. J., Gearry, R. B., Roberts, R. L., Zhang, M., Barclay, M. L., & Begg, E. J. (2007). Breast-feeding during maternal use of azathioprine [Comment]. Annals of Pharmacotherapy, 41(4), 719-720.

Gearry, R. B., Lea, R. A., Roberts, R. L., Chambers, G. K., Barclay, M. L., & Kennedy, M. A. (2006). CARD15 allele frequency differences in New Zealand Maori: Ancestry specific susceptibility to Crohn's disease in New Zealand? [Letter]. Gut, 55, 580. doi: 10.1136/gut.2005.085464

Stamp, L., Roberts, R., Kennedy, M., Barclay, M., O'Donnell, J., & Chapman, P. (2006). The use of low dose methotrexate in rheumatoid arthritis: Are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomedicine & Pharmacotherapy, 60, 678-687.

Gearry, R. B., Aitken, J. M., Roberts, R. L., Ismail, S. L., Keenan, J., & Barclay, M. L. (2005). Gastrointestinal: Mycobacterium avium paratuberculosis and Crohn's disease. Journal of Gastroenterology & Hepatology, 20(12), 1943. doi: 10.1111/j.1440-1746.2005.04187.x

More publications...